Literature DB >> 14621327

Sexually transmitted diseases, HIV, and AIDS in women.

Susan E Cohn1, Rebecca A Clark.   

Abstract

Several key points are addressed in this article including the following: 1. Most women with HIV are of reproductive age (20 to 44 years of age), acquire their HIV infection through heterosexual contact, and are women of color (African American or Latina). 2. Sex does not seem to alter substantially the presentation or natural history of HIV with the exception of unique gynecologic manifestations. 3. Women with HIV are more likely to have disease caused by HPV (such as abnormal Pap smears or warts), more severe Candida vulvovaginitis, and PID. 4. HIV is transmitted by sexual contact, exposure to infected blood or tissues, and breast-feeding. The risk of perinatal transmission has dramatically dropped to 1% to 2% with the advent of potent ARV therapy. 5. Several potent ARV therapies are now available and have greatly prolonged and enhanced the quality of life among persons with HIV. 6. New approaches to prevention of HIV transmission include use of topical microbicides, vaccines, and use of potent ARV therapies following exposure to HIV.

Entities:  

Mesh:

Year:  2003        PMID: 14621327     DOI: 10.1016/s0025-7125(03)00062-2

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  9 in total

1.  Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.

Authors:  R N Fichorova; F Zhou; V Ratnam; V Atanassova; S Jiang; N Strick; A R Neurath
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Induction of secretory aspartyl proteinase of Candida albicans by HIV-1 but not HSV-2 or some other microorganisms associated with vaginal environment.

Authors:  Ilknur Tosun; Faruk Aydin; Neşe Kaklikkaya; Murat Erturk
Journal:  Mycopathologia       Date:  2005-02       Impact factor: 2.574

3.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 5.  The rationale for probiotics in female urogenital healthcare.

Authors:  Gregor Reid; Jeremy Burton; Estelle Devillard
Journal:  MedGenMed       Date:  2004-03-29

6.  Semen lactoferrin promotes CCL20 production by epithelial cells: Involvement in HIV transmission.

Authors:  Alan Grupioni Lourenço; Marilena Chinalli Komesu; Alcyone Artioli Machado; Silvana Maria Quintana; Thomas Bourlet; Bruno Pozzetto; Olivier Delézay
Journal:  World J Virol       Date:  2014-05-12

7.  Sphingomyelinase activity of Trichomonas vaginalis extract and subfractions.

Authors:  Francisco González-Salazar; Jesús N Garza-González; Carlos E Hernandez-Luna; Benito David Mata-Cárdenas; Pilar Carranza-Rosales; Jorge Enrique Castro-Garza; Magda Elizabeth Hernández-García; Javier Vargas-Villarreal
Journal:  Biomed Res Int       Date:  2013-08-19       Impact factor: 3.411

8.  Genome sequence of Lactobacillus pentosus KCA1: vaginal isolate from a healthy premenopausal woman.

Authors:  Kingsley C Anukam; Jean M Macklaim; Gregory B Gloor; Gregor Reid; Jos Boekhorst; Bernadet Renckens; Sacha A F T van Hijum; Roland J Siezen
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

Review 9.  Mucosal immunity in the female genital tract, HIV/AIDS.

Authors:  Juliana Reis Machado; Marcos Vinícius da Silva; Camila Lourencini Cavellani; Marlene Antônia dos Reis; Maria Luiza Gonçalves dos Reis Monteiro; Vicente de Paula Antunes Teixeira; Rosana Rosa Miranda Corrêa
Journal:  Biomed Res Int       Date:  2014-09-15       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.